CRL · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-11-04 · Importance 31 · Surprise 32

Revenue for the nine months ended September 26, 2026 decreased 1.3% to $2,982.6 million from $3,021.2 million, while third-quarter revenue fell 2.2% to $982.7 million. Nine-month service revenue declined 2.5% to $2,386.8 million, while product revenue rose 3.7% to $595.9 million. DSA revenue decreased 0.6% to $1,799.8 million, Manufacturing revenue decreased 2.2% to $557.5 million, and RMS revenue decreased 2.3% to $625.4 million; divestitures were the primary drag. In the third quarter, regulated safety assessment services added $33.5 million to DSA revenue, while China small research model product revenue rose $4.9 million and North America small research model product revenue fell $3.8 million in RMS.

Key facts

• Consolidated revenue decreased 1.3% to $2,982.6 million in the nine months ended September 26, 2026, from $3,021.2 million in the comparable 2025 period. source
• Consolidated revenue decreased 2.2% to $982.7 million in the three months ended September 26, 2026, from $1,004.9 million in the comparable 2025 period. source
• The consolidated revenue declines in the three- and nine-month periods primarily reflected lower Manufacturing and RMS revenue from the CDMO and Cell Solutions divestiture and lower DSA revenue from the European Discovery divestiture. source